25 results about "Oncology field" patented technology

The invention provides a natural language-driven scientific research naming and ranking patient matching method and system, belongs to the technical field of artificial intelligence and medical information processing, and solves the problems of high manual workload, difficulty in semantic analysis, insufficient logical reasoning ability and the like in an existing cancer patient screening mode. The method comprises the following steps: analyzing a containing and arranging condition in a natural language text form in the tumor field to obtain a structured containing and arranging condition logic rule set; performing entity recognition, relation extraction and portrait construction on the multi-modal medical record of the cancer patient to obtain a comprehensive cancer portrait of the patient; and performing logic matching on the comprehensive cancer portrait of the patient and the structured accommodating and discharging condition rule set, determining whether the patient meets accommodating and discharging conditions, and generating a traceable matching interpretation path. The method can effectively solve the problems of large manual workload, difficulty in semantic analysis, insufficient logical reasoning ability and the like in the existing cancer patient screening mode.

The present invention relates to the nanoparticles (NP) of the invention, compositions thereof and their use as therapeutic agents, in particular in the field of oncology and / or as imaging agents. The NPs consist of first nanoparticles of at least one high-Z metal oxide material, to which smaller second nanoparticles are covalently bonded at the surface of the first nanoparticles. The second nanoparticles consist of a) at least one noble metal or at least one metal oxide, metal sulfide, metal selenide or metal sulfide / selenide as a Fenton or Fenton-like reaction catalyst. The NPs of the invention produce a surprising therapeutic effect when exposed to ionizing radiation such as X-rays, gamma-rays, protons, neutrons, radioisotopes and / or electron beams. Therefore, these NPs can be used as radiosensitizers in the field of oncology. These nanoparticles can also be used as contrast agents.

The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms expression; and also to screening methods for anti-cancer stem cells agents.

The invention discloses a lung adenocarcinoma prognosis and immune infiltration related prediction model. By deeply mining data in TCGA and GEO databases, a prognosis model based on eight pyroptosis related genes is constructed, and compared with a traditional method, the five-year survival prognosis of a lung adenocarcinoma patient can be more accurately predicted. A verification result shows that the model has relatively high accuracy (AUC = 0.687) in prediction of the total survival of one year, and through Kaplan-Meier analysis and Log-Rank inspection, survival differences of patients in high and low risk groups in a training set and a verification set are remarkably distinguished. The research method and the model have strong universality, provide important reference for research and application of a pyroptosis related mechanism in other cancer types, promote the progress of the oncology field in the research related to the pyroptosis mechanism, and have wide clinical application value.

The invention discloses a genetic molecular marker related to colorectal cancer auxiliary diagnosis and application of the genetic molecular marker, and belongs to the field of genetic engineering and oncology. 37 SNPs significantly related to the colorectal cancer onset risk are screened out, the colorectal cancer auxiliary diagnosis kit prepared based on 37 markers is helpful for clinicians to rapidly master the genetic risk of colorectal cancer onset, powerful support is provided for early prevention measures, and the colorectal cancer auxiliary diagnosis kit is suitable for multiple populations and has a wide application prospect. The problem that a conventional genetic risk prediction model is not compatible with people in China and Europe and America is effectively solved.

The present invention relates to the field of oncology. In particular, the present invention relates to biomarkers for colorectal cancer and their use for diagnosing or staging colorectal cancer. The biomarkers of the present invention allow for the sensitive and accurate diagnosis of colorectal cancer and the differentiation between non-metastatic and metastatic colorectal cancer.

The present invention relates to the field of oncology and provides compounds, compositions, uses and methods for treating cancer, particularly stroma-rich tumors, by selectively targeting cancer-associated fibroblasts (CAFs). CAF targeting is one strategy for enhancing the effectiveness of immunotherapy and can improve the patient response rate. Furthermore, this specificity in the target and related pathways reduces damage to normal tissues.

The invention relates to the field of oncology, in particular to application of a cancer immunotherapy target and a diagnosis and prognosis prediction biomarker. Wherein at least one marker in the EGFR / Wnt / beta-catenin-LINC00973-miRNA-CD55 / CD59 pathway can be used for evaluating the sensitivity or the prognosis of the cancer immunotherapy.

The present invention discloses a method for treating cancer in a subject by administering a pharmaceutical composition comprising a compound of Formula (I) or its salt, co-crystal, or solvate. The disclosed method offers a promising approach to treat cancers including recalcitrant cancers, thereby providing a valuable contribution to the field of oncology.

The invention discloses a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP and application, and belongs to the field of medical immunology and oncology. The invention discloses a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP. The amino acid sequence of the epitope peptide comprises any one or more of the following: KWVESIFLI; tFMNKFIYEI, fLYAPTILL is used as a template; kYIQESQAL is selected from the group consisting of the following components; the amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that an anti-tumor immune effect is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for liver cancer, can also be used for preparing quantitative detection reagents for detecting specific T cells of liver cancer related antigen AFP, and have potential application value in prevention, treatment and diagnosis of liver cancer.

The disclosure is in the field of immunology and oncology, especially for treating, preventing, or inhibiting proliferative diseases, particularly cancer, infectious diseases and disorders associated with dysfunction of TNF cytokines. The disclosure relates to a novel SPD-TNFSF fusion protein including a TNF-superfamily (TNFSF) ligand, or receptor binding domain thereof, fused to a coiled-coil domain of surfactant protein-D (SPD). Also provided a trimeric or multimeric fusion protein including a plurality of SPD-TNFSF fusion proteins. The disclosure also provides an expression vector as mRNA, plasmid or virus including an isolated nucleotide sequence encoding the SPD-TNFSF fusion protein and a cell or a pharmaceutical composition including thereof.

The present invention relates to the treatment of cancer and to the prevention of cancer growth and / or metastasis. In particular, the invention relates to cellular and acellular vaccines containing C3d, a proteolytic product of complement (C3), and methods of enhancing a host immune response (e.g., a T cell mediated immune response) against cancers using same. Compositions and methods of the invention find use, alone or in conjunction with other cancer therapies, in treating lymphoma and / or cancers that develop and / or persist by evading host immune surveillance and / or responses (e.g., T-cell mediated immune responses). Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.

The present disclosure relates generally to the field of medical oncology and, in particular, to methods and kits for identifying and treating neuroendocrine carcinomas, such as small cell neuroendocrine (SCN) tumors. Certain aspects of the present disclosure can include methods of diagnosing a patient with a neuroendocrine carcinoma, methods of determining a survival prognosis in a patient diagnosed with a neuroendocrine carcinoma, compositions that effectively inhibits or decreases an expression level of a hepatocyte cell adhesion molecule 2 (HEPACAM2) biomarker in vivo or ex vivo, and methods of treating a patient having, or suspected of having, a neuroendocrine carcinoma.

The present invention relates to the field of oncology. It more particularly relates to a method for evaluating the prognosis or the response to a therapeutic treatment of a subject having a squamous cell carcinoma by assessing the multinucleated giant cells status of a SCC tumor of the subject. This method may be advantageously computer-implemented for ease of use in the clinic.

The invention discloses a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP and application, and belongs to the field of medical immunology and oncology. The invention relates to a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP. The amino acid sequence of the epitope peptide comprises any one or more of AQFVQEATYK, AQFVQEATYK, AQFVQEATYK and AQFVQEATYK. FLYAPTILLW, FLYAPTILLW; sLLNQHACAV (Solvent Level Normal The amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that an anti-tumor immune effect is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for liver cancer, can also be used for preparing quantitative detection reagents for detecting specific T cells of liver cancer related antigen AFP, and have potential application value in prevention, treatment and diagnosis of liver cancer.

The invention discloses a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP and application, and belongs to the field of medical immunology and oncology. The invention discloses a thymus dependent lymphocyte antigen epitope peptide of a liver cancer associated antigen AFP. The amino acid sequence of the epitope peptide comprises any one or more of the following: AITVTKLSQK; yLQNAFLVA (Yttrium Laboratory Quantitative FSDDKFIFHK, FSDDKFIFHK The amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that an anti-tumor immune effect is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for liver cancer, can also be used for preparing quantitative detection reagents for detecting specific T cells of liver cancer related antigen AFP, and have potential application value in prevention, treatment and diagnosis of liver cancer.

The present disclosure relates to the field of immunooncology. More specifically, the present disclosure relates to methods and compositions for performing single cell phenotypic and functional analysis of immune cells and cancer cells present within a tumor microenvironment. The methods and compositions allow for determining whether a subject having a solid tumor is likely to respond to a particular immunomodulator, and also allow for treating a solid tumor in a subject by helping select an immunomodulator suitable for treating a solid tumor in a subject.

The invention provides a methylation-related genetic biomarker related to colorectal cancer and application of the methylation-related genetic biomarker, and belongs to the field of genetic engineering and oncology. The colorectal cancer auxiliary diagnosis kit prepared on the basis of the biomarker is helpful for clinicians to quickly master genetic risks of colorectal cancer morbidity, provides reliable support for early screening and taking intervention measures, and has general applicability to Chinese population.

The present invention relates to the field of oncology and more particularly to the evaluation of risk factors for radiotherapy treatment in a patient with, for example, cancer in the head or neck area, in order to determine whether they are able to withstand further irradiation without major or even fatal toxicological risk. Abstract: Figure 1

To provide compositions and methods for inhibiting or reversing the depletion of T cells.SOLUTION: The present invention relates to T cell compositions related to therapy and treatment, and methods of using the same. In particular, the present invention provides chimeric antigen receptor (CAR) T cells that are modified to maintain functionality under conditions in which the depletion of unmodified CAR T cells is recognized. Compositions and methods disclosed herein find use in inhibiting or reversing the depletion of CAR T cells (e.g., by modulating CAR surface expression), thereby enhancing a CAR T cell function. Compositions and methods of the present invention are used under clinical and research situation, for example, within the fields of biology, immunology, medicine, and oncology.SELECTED DRAWING: None

The present invention relates to the field of oncology. Specifically, the present invention relates to the use of protein biomarkers for the diagnosis of gastric cancer. The protein biomarkers are selected from one or a combination of two or more of GSTP1, COL15A1, VMO1, and ANGPTL2. The biomarkers of the present invention can sensitively and accurately diagnose gastric cancer.

The present invention relates to the field of medicine, particularly in the field of oncology. In particular, the present invention provides novel compounds that can be used for the treatment of various cancers such as glioblastoma, colorectal cancer or breast cancer. The present disclosure also relates to pharmaceutical compositions containing the disclosed compounds.

The invention discloses a thymus dependent lymphocyte antigen epitope peptide of a lung cancer associated antigen Cyfra21-1 and application, and belongs to the field of medical immunology and oncology. The invention relates to a thymus dependent lymphocyte antigen epitope peptide of a lung cancer associated antigen Cyfra21-1. The amino acid sequence of the epitope peptide comprises any one or more of the following: EVKIRDWYQK; a YQKQGPGPSR (YQKQGPGPSR) A DYSHYYTTI (Transmission Time Interval); the amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that an anti-tumor immune effect is exerted; the antigen peptides can be used for preparing therapeutic and preventive vaccines for lung cancer, can also be used for preparing quantitative detection reagents for detecting specific T cells of the lung cancer related antigen Cyfra21-1, and have potential application value in prevention, treatment and diagnosis of lung cancer.

The present invention is in the field of immunology and oncology, in particular for the treatment, prevention or inhibition of proliferative diseases, in particular cancer, infectious diseases and conditions associated with TNF cytokine dysfunction. The present invention relates to a novel SPD-TNFSF fusion protein comprising a TNF-superfamily (TNFSF) ligand, or a receptor binding domain thereof, fused to a coiled-coil domain of a surface active protein-D (SPD). A trimeric or multimeric fusion protein comprising a plurality of the SPD-TNFSF fusion proteins is also provided. The invention also provides an expression vector (such as mRNA, plasmid or virus) comprising the isolated nucleotide sequence encoding the SPD-TNFSF fusion protein and a cell or pharmaceutical composition comprising the same.

The present invention relates to the field of oncology and provides compounds, compositions, uses and methods for treating cancer, in particular mesenchymal-rich tumors, by selectively targeting cancer-associated fibroblasts (CAFs). CAF targeting is a strategy to enhance the efficacy of immunotherapy and may increase patient response. Furthermore, damage to normal tissue is reduced by this specificity of targets and related pathways.